268 related articles for article (PubMed ID: 17705230)
1. SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.
Malik G; Rojahn E; Ward MD; Gretzer MB; Partin AW; Semmes OJ; Veltri RW
Prostate; 2007 Oct; 67(14):1565-75. PubMed ID: 17705230
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.
Gretzer MB; Chan DW; van Rootselaar CL; Rosenzweig JM; Dalrymple S; Mangold LA; Partin AW; Veltri RW
Prostate; 2004 Sep; 60(4):325-31. PubMed ID: 15264244
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.
Malik G; Ward MD; Gupta SK; Trosset MW; Grizzle WE; Adam BL; Diaz JI; Semmes OJ
Clin Cancer Res; 2005 Feb; 11(3):1073-85. PubMed ID: 15709174
[TBL] [Abstract][Full Text] [Related]
4. [Screening of differentially expressed proteins associated with directional highly lymphatic metastasis in ovarian carcinoma cell lines using SELDI-TOF-MS technology].
Guan X; Li DR; Wang Q; Li L; Ruan HY; Zhang W
Ai Zheng; 2008 Nov; 27(11):1155-60. PubMed ID: 19000445
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers.
Rai AJ; Stemmer PM; Zhang Z; Adam BL; Morgan WT; Caffrey RE; Podust VN; Patel M; Lim LY; Shipulina NV; Chan DW; Semmes OJ; Leung HC
Proteomics; 2005 Aug; 5(13):3467-74. PubMed ID: 16052624
[TBL] [Abstract][Full Text] [Related]
6. Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
O'Gorman D; Howard JC; Varallo VM; Cadieux P; Bowley E; McLean K; Pak BJ; Gan BS
Clin Invest Med; 2006 Jun; 29(3):136-45. PubMed ID: 17058431
[TBL] [Abstract][Full Text] [Related]
7. Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS.
Miguet L; Bogumil R; Decloquement P; Herbrecht R; Potier N; Mauvieux L; Van Dorsselaer A
J Proteome Res; 2006 Sep; 5(9):2258-69. PubMed ID: 16944938
[TBL] [Abstract][Full Text] [Related]
8. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
Liu XP; Shen J; Li ZF; Yan L; Gu J
Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
[TBL] [Abstract][Full Text] [Related]
9. Detection and identification of potential biomarkers of non-small cell lung cancer.
Yang Y; Zhao S; Fan Y; Zhao F; Liu Q; Hu W; Liu D; Fan K; Wang J; Wang J
Technol Cancer Res Treat; 2009 Dec; 8(6):455-66. PubMed ID: 19925029
[TBL] [Abstract][Full Text] [Related]
10. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions.
Le L; Chi K; Tyldesley S; Flibotte S; Diamond DL; Kuzyk MA; Sadar MD
Clin Chem; 2005 Apr; 51(4):695-707. PubMed ID: 15695329
[TBL] [Abstract][Full Text] [Related]
11. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
Geng X; Wang F; Li YG; Zhu GP; Zhang WM
J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
[TBL] [Abstract][Full Text] [Related]
12. [Application of laser capture microdissection and surface-enhanced laser desorption ionization time-of-flight mass spectrometry to screen biomarkers for early diagnosis of lung adenocarcinoma].
Tian YX; Yang SY; Nan YD; Zhang W; Yu JK; Zheng S
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):157-61. PubMed ID: 19292069
[TBL] [Abstract][Full Text] [Related]
13. SELDI-TOF-MS of saliva: methodology and pre-treatment effects.
Schipper R; Loof A; de Groot J; Harthoorn L; Dransfield E; van Heerde W
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):45-53. PubMed ID: 17070117
[TBL] [Abstract][Full Text] [Related]
14. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.
McLerran D; Grizzle WE; Feng Z; Thompson IM; Bigbee WL; Cazares LH; Chan DW; Dahlgren J; Diaz J; Kagan J; Lin DW; Malik G; Oelschlager D; Partin A; Randolph TW; Sokoll L; Srivastava S; Srivastava S; Thornquist M; Troyer D; Wright GL; Zhang Z; Zhu L; Semmes OJ
Clin Chem; 2008 Jan; 54(1):53-60. PubMed ID: 18024530
[TBL] [Abstract][Full Text] [Related]
15. Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform.
Yu Z; Yu JK; Fang XF; Yuan Y; Shen H
Hepatogastroenterology; 2013 Oct; 60(127):1800-4. PubMed ID: 24624447
[TBL] [Abstract][Full Text] [Related]
16. Targeting phosphoprotein profiling by combination of hydroxyapatite-based phosphoprotein enrichment and SELDI-TOF MS.
Vormbrock I; Kaber G; Hartwig S; Eckel J; Schrör K; Lehr S
Arch Physiol Biochem; 2010; 116(4-5):181-7. PubMed ID: 20726833
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
18. Application of SELDI-TOF in N-glycopeptides profiling of the urine from patients with endometrial, ovarian and cervical cancer.
Mu AK; Lim BK; Aminudin N; Hashim OH; Shuib AS
Arch Physiol Biochem; 2016 Jul; 122(3):111-6. PubMed ID: 26849673
[TBL] [Abstract][Full Text] [Related]
19. Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.
Hegmans JP; Veltman JD; Fung ET; Verch T; Glover C; Zhang F; Allard WJ; T'Jampens D; Hoogsteden HC; Lambrecht BN; Aerts J
Technol Cancer Res Treat; 2009 Oct; 8(5):323-32. PubMed ID: 19754208
[TBL] [Abstract][Full Text] [Related]
20. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
